Cargando…

Current Targeted Therapies for the Fight against Non-Small Cell Lung Cancer

Lung cancers contribute to the greatest number of cancer-related deaths worldwide and still pose challenges in response to current treatment strategies. Non-small cell lung cancer (NSCLC) accounts for over 85% of lung cancers diagnosed in the United States and novel therapeutics are needed for the t...

Descripción completa

Detalles Bibliográficos
Autores principales: Mustachio, Lisa Maria, Roszik, Jason
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695293/
https://www.ncbi.nlm.nih.gov/pubmed/33182254
http://dx.doi.org/10.3390/ph13110374
_version_ 1783615155487113216
author Mustachio, Lisa Maria
Roszik, Jason
author_facet Mustachio, Lisa Maria
Roszik, Jason
author_sort Mustachio, Lisa Maria
collection PubMed
description Lung cancers contribute to the greatest number of cancer-related deaths worldwide and still pose challenges in response to current treatment strategies. Non-small cell lung cancer (NSCLC) accounts for over 85% of lung cancers diagnosed in the United States and novel therapeutics are needed for the treatment of this disease. First and second generation targeted therapies against specific mutated or rearranged oncogenes in NSCLCs show anti-tumor activity and also increase survival. However, many NSCLC patients eventually develop resistance to these therapies or do not properly respond if they have central nervous system metastases. Thus, this review summarizes recent developments and findings related to the generation of novel targeted therapies recently or currently being developed to tackle hurdles that prior therapies were not able to overcome.
format Online
Article
Text
id pubmed-7695293
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76952932020-11-28 Current Targeted Therapies for the Fight against Non-Small Cell Lung Cancer Mustachio, Lisa Maria Roszik, Jason Pharmaceuticals (Basel) Review Lung cancers contribute to the greatest number of cancer-related deaths worldwide and still pose challenges in response to current treatment strategies. Non-small cell lung cancer (NSCLC) accounts for over 85% of lung cancers diagnosed in the United States and novel therapeutics are needed for the treatment of this disease. First and second generation targeted therapies against specific mutated or rearranged oncogenes in NSCLCs show anti-tumor activity and also increase survival. However, many NSCLC patients eventually develop resistance to these therapies or do not properly respond if they have central nervous system metastases. Thus, this review summarizes recent developments and findings related to the generation of novel targeted therapies recently or currently being developed to tackle hurdles that prior therapies were not able to overcome. MDPI 2020-11-09 /pmc/articles/PMC7695293/ /pubmed/33182254 http://dx.doi.org/10.3390/ph13110374 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Mustachio, Lisa Maria
Roszik, Jason
Current Targeted Therapies for the Fight against Non-Small Cell Lung Cancer
title Current Targeted Therapies for the Fight against Non-Small Cell Lung Cancer
title_full Current Targeted Therapies for the Fight against Non-Small Cell Lung Cancer
title_fullStr Current Targeted Therapies for the Fight against Non-Small Cell Lung Cancer
title_full_unstemmed Current Targeted Therapies for the Fight against Non-Small Cell Lung Cancer
title_short Current Targeted Therapies for the Fight against Non-Small Cell Lung Cancer
title_sort current targeted therapies for the fight against non-small cell lung cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695293/
https://www.ncbi.nlm.nih.gov/pubmed/33182254
http://dx.doi.org/10.3390/ph13110374
work_keys_str_mv AT mustachiolisamaria currenttargetedtherapiesforthefightagainstnonsmallcelllungcancer
AT roszikjason currenttargetedtherapiesforthefightagainstnonsmallcelllungcancer